IL160498A0 - Pharmaceutical compositions comprising colloidal silicon dioxide - Google Patents

Pharmaceutical compositions comprising colloidal silicon dioxide

Info

Publication number
IL160498A0
IL160498A0 IL16049802A IL16049802A IL160498A0 IL 160498 A0 IL160498 A0 IL 160498A0 IL 16049802 A IL16049802 A IL 16049802A IL 16049802 A IL16049802 A IL 16049802A IL 160498 A0 IL160498 A0 IL 160498A0
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
silicon dioxide
colloidal silicon
colloidal
dioxide
Prior art date
Application number
IL16049802A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9922916&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL160498(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL160498A0 publication Critical patent/IL160498A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
IL16049802A 2001-09-28 2002-09-27 Pharmaceutical compositions comprising colloidal silicon dioxide IL160498A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0123400.4A GB0123400D0 (en) 2001-09-28 2001-09-28 Organic compounds
PCT/EP2002/010890 WO2003028705A1 (en) 2001-09-28 2002-09-27 Pharmaceutical compositions comprising colloidal silicon dioxide

Publications (1)

Publication Number Publication Date
IL160498A0 true IL160498A0 (en) 2004-07-25

Family

ID=9922916

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16049802A IL160498A0 (en) 2001-09-28 2002-09-27 Pharmaceutical compositions comprising colloidal silicon dioxide
IL160498A IL160498A (en) 2001-09-28 2004-02-19 Pharmaceutical compositions in the form of dispersible tablet comprising a solid dispersion of rapamycin or ascomycin, a disintegrant and colloidal silicon dioxide and process for producing said tablet

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL160498A IL160498A (en) 2001-09-28 2004-02-19 Pharmaceutical compositions in the form of dispersible tablet comprising a solid dispersion of rapamycin or ascomycin, a disintegrant and colloidal silicon dioxide and process for producing said tablet

Country Status (30)

Country Link
US (4) US20040254210A1 (OSRAM)
EP (2) EP2193788B1 (OSRAM)
JP (2) JP2005507897A (OSRAM)
KR (1) KR100626785B1 (OSRAM)
CN (3) CN101912392A (OSRAM)
AR (2) AR036643A1 (OSRAM)
AT (1) ATE485813T1 (OSRAM)
BR (2) BR0212922A (OSRAM)
CA (1) CA2458455C (OSRAM)
CO (1) CO5390072A1 (OSRAM)
CY (2) CY1111119T1 (OSRAM)
DE (1) DE60238131D1 (OSRAM)
DK (2) DK1432408T3 (OSRAM)
EC (1) ECSP024323A (OSRAM)
ES (2) ES2560106T3 (OSRAM)
GB (1) GB0123400D0 (OSRAM)
HU (1) HU229991B1 (OSRAM)
IL (2) IL160498A0 (OSRAM)
MX (1) MXPA04002814A (OSRAM)
MY (1) MY150060A (OSRAM)
NO (1) NO333892B1 (OSRAM)
NZ (2) NZ542273A (OSRAM)
PE (1) PE20030602A1 (OSRAM)
PL (1) PL209704B1 (OSRAM)
PT (2) PT2193788E (OSRAM)
RU (1) RU2322970C2 (OSRAM)
SI (1) SI1432408T1 (OSRAM)
TW (1) TWI242449B (OSRAM)
WO (1) WO2003028705A1 (OSRAM)
ZA (1) ZA200401300B (OSRAM)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
WO2003064383A2 (en) 2002-02-01 2003-08-07 Ariad Gene Therapeutics, Inc. Phosphorus-containing compounds & uses thereof
JP2006506353A (ja) * 2002-09-17 2006-02-23 ワイス 経口処方
US20060035875A1 (en) * 2002-10-09 2006-02-16 Yukimasa Shiotsu Remedy for hormone-dependent cancer
DE10351448A1 (de) * 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
ATE548049T1 (de) * 2005-06-09 2012-03-15 Hansa Medical Ab Verwendung von ides proteinase (von s. pyogenes) zur behandlung von autoimmunkrankheiten und transplantatabstossung
US20080161335A1 (en) * 2006-11-14 2008-07-03 Vladyka Ronald S Oral formulations
EA019893B1 (ru) 2007-02-23 2014-07-30 Джилид Сайэнс, Инк. Фармацевтическая композиция и способ лечения вич-инфекции
EP3006032A1 (en) 2008-05-02 2016-04-13 Gilead Sciences, Inc. The use of solid carrier particles to improve the processability of a pharmaceutical agent
CN101444503B (zh) * 2008-12-31 2011-02-02 江苏大学 一种水飞蓟宾高效长效制剂及其制法
CN101444494B (zh) * 2008-12-31 2011-03-30 江苏大学 难溶性药物高效长效缓释制剂及其制法
CN101439025B (zh) * 2008-12-31 2011-05-11 江苏大学 一种水飞蓟素高效长效制剂及其制法
WO2010085520A1 (en) * 2009-01-21 2010-07-29 Mylan Inc. Disintegrable formulations of lanthanum carbonate
US8728516B2 (en) 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
TWI471321B (zh) 2009-06-08 2015-02-01 亞培公司 Ｂｃｌ－２族群抑制劑之口服醫藥劑型
AU2010336518B2 (en) 2009-12-22 2014-03-06 Abbvie Inc. ABT-263 capsule
US20170087134A1 (en) * 2010-07-12 2017-03-30 Salix Pharmaceuticals, Ltd Formulations of rifaximin and uses thereof
US20120045433A1 (en) * 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
CA3152557A1 (en) 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
UY33746A (es) 2010-11-23 2012-06-29 Abbott Lab Método de tratamiento que usa inhibidores selectivos de bcl-2
SI2643322T1 (en) 2010-11-23 2018-01-31 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
DE102011052396A1 (de) * 2011-08-04 2013-02-07 Gelita Ag Verfahren zur Herstellung einer stabilen Dispersion von Nanopartikeln, hergestellte Dispersion und deren Verwendung
KR101151890B1 (ko) * 2011-08-11 2012-05-31 동아제약주식회사 안정화 및 가용화된 시롤리무스 유도체 조성물의 제조방법
EP2763663B1 (en) 2011-10-06 2017-12-27 Novartis AG Pharmaceutical compositions comprising 40-o-(2-hydroxy)ethyl-rapamycin
CN102793673A (zh) * 2012-09-07 2012-11-28 中国药科大学 一种小檗碱磷脂复合物固体分散体及其制备方法
US10172789B2 (en) 2013-01-24 2019-01-08 Palvella Therapeutics Llc Compositions for transdermal delivery of mTOR inhibitors
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TW201503912A (zh) * 2013-03-19 2015-02-01 Novartis Ag 包含癌莫事（ｅｖｅｒｏｌｉｍｕｓ）之醫藥組合物
US20150140036A1 (en) 2013-11-13 2015-05-21 Novartis Institutes For Biomedical Research, Inc. Low, immune enhancing, dose mtor inhibitors and uses thereof
CN103610646B (zh) * 2013-12-05 2015-07-15 江苏奥赛康药业股份有限公司 一种含依维莫司的组合物及其制备方法和含有这一组合物的药物制剂
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
EP3193915A1 (en) 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
WO2016135740A1 (en) 2015-02-23 2016-09-01 Natco Pharma Limited Process for preparing stable oral compositions of everolimus
HK1245095A1 (zh) 2015-05-20 2018-08-24 Novartis Ag 依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合
EP3329916A4 (en) 2015-07-28 2019-03-20 Nippon Kayaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION COMPRISING RAPAMYCIN OR A DERIVATIVE THEREOF, AND PROCESS FOR PRODUCING THE SAME
JP6855470B2 (ja) * 2016-05-27 2021-04-07 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
RS63751B1 (sr) 2016-09-30 2022-12-30 Salix Pharmaceuticals Inc Čvrsti disperzioni oblici rifaksimina
WO2018096402A1 (en) 2016-11-23 2018-05-31 Novartis Ag Methods of enhancing immune response with everolimus, dactolisib or both
IL302385B2 (en) 2017-01-06 2024-06-01 Palvella Therapeutics Inc Non-aqueous preparations of mTOR inhibitors and methods of use
US11504333B2 (en) 2017-07-05 2022-11-22 Novartis Ag Pharmaceutical composition
CN108125918B (zh) * 2018-01-12 2020-06-23 杭州中美华东制药有限公司 依维莫司药物组合物
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
EP3817743A4 (en) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE
US20230201234A1 (en) * 2020-06-01 2023-06-29 Shilpa Medicare Ltd Fast dispersible pharmaceutical composition comprising capecitabine
WO2022219652A1 (en) * 2021-04-17 2022-10-20 Bdr Pharmaceuticals International Private Limited Novel sublingual pharmaceutical formulations for everolimus
CN119523923A (zh) * 2024-11-21 2025-02-28 华中药业股份有限公司 一种左炔诺孕酮片及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8608080D0 (en) 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
US5211958A (en) * 1987-11-30 1993-05-18 Gist-Brocades, N.V. Pharmaceutical composition and process for its preparation
US4920102A (en) * 1988-04-18 1990-04-24 Eli Lilly And Company Method for treating gastrointestinal disorders
IT1246383B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per il mascheramento del sapore di farmaci
DE69227773T2 (de) 1991-07-03 1999-05-20 Pharmacia & Upjohn Co., Kalamazoo, Mich. Tabletten mit hohem gehalt an colestipolhydrochlorid
US5605889A (en) 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
PE52896A1 (es) 1994-10-26 1996-12-12 Novartis Ag Composicion farmaceutica
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
DE19544507B4 (de) 1995-11-29 2007-11-15 Novartis Ag Cyclosporin enthaltende Präparate
IL125214A0 (en) * 1996-02-29 1999-03-12 Fujisawa Pharmaceutical Co Beta-lactam antibiotic-containing tablet and method for producing the same
JP4064476B2 (ja) 1996-03-29 2008-03-19 エラワン ファーマスーティカル リサーチ アンドラボラトリー カンパニー リミテッド 二酸化珪素を有する球状凝集した澱粉
US6056974A (en) * 1996-04-26 2000-05-02 Shionogi & Co., Ltd. Rapid-release S1452 tablets
GB2318511A (en) 1996-10-23 1998-04-29 Eurand Int Process for the preparation of a pharmaceutical composition for rapid suspension in water
NZ335737A (en) * 1996-11-12 2000-09-29 Pharmacia & Upjohn Ab Compact member comprising a plurality of porous cellulose matrices (PCMs)
US5989591A (en) 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US6080427A (en) * 1997-04-17 2000-06-27 Bristol-Myers Squibb Company Cefadroxil monohydrate tablet formulation
CN1133424C (zh) 1997-06-13 2004-01-07 惠氏公司 口服给药的雷怕霉素制剂
PT1421939E (pt) 1998-03-26 2010-07-12 Astellas Pharma Inc Preparaã†o da libertaã†o sustentada de um composto de macrëlido como tracolimus
FR2785538B1 (fr) * 1998-11-06 2004-04-09 Prographarm Laboratoires Comprime a delitement rapide perfectionne
GB9826656D0 (en) * 1998-12-03 1999-01-27 Novartis Ag Organic compounds
AU2944700A (en) * 1999-03-15 2000-10-04 Kaken Pharmaceutical Co., Ltd. Quickly disintegrating tablets and process for producing the same
FR2793690B1 (fr) 1999-03-30 2003-01-03 Cll Pharma Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique
DE69930621T2 (de) * 1999-05-21 2006-11-09 Kissei Pharmaceutical Co., Ltd., Matsumoto Medizinische zusammensetzungen zur unmittelbaren freisetzung bei oraler anwendung
GB0008785D0 (en) 2000-04-10 2000-05-31 Novartis Ag Organic compounds
US20020076437A1 (en) 2000-04-12 2002-06-20 Sanjeev Kothari Flashmelt oral dosage formulation
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
EP1855655A2 (en) 2005-02-25 2007-11-21 F. Hoffmann-Roche AG Tablets with improved drug substance dispersibility
TWI347942B (en) 2005-06-22 2011-09-01 Lundbeck & Co As H Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base

Also Published As

Publication number Publication date
MY150060A (en) 2013-11-29
HUP0402394A3 (en) 2005-12-28
BRPI0212922B1 (pt) 2018-03-13
PT2193788E (pt) 2016-02-23
CN101912392A (zh) 2010-12-15
DK2193788T3 (en) 2016-02-01
IL160498A (en) 2011-07-31
TWI242449B (en) 2005-11-01
ATE485813T1 (de) 2010-11-15
US20040254210A1 (en) 2004-12-16
EP1432408B8 (en) 2011-03-02
EP1432408A1 (en) 2004-06-30
ECSP024323A (es) 2003-04-25
HU229991B1 (en) 2015-04-28
CA2458455A1 (en) 2003-04-10
US20120289536A1 (en) 2012-11-15
CY1117164T1 (el) 2017-04-05
MXPA04002814A (es) 2004-07-05
US20110306630A1 (en) 2011-12-15
US8617598B2 (en) 2013-12-31
DK1432408T3 (da) 2011-02-07
NO333892B1 (no) 2013-10-14
RU2322970C2 (ru) 2008-04-27
CN1561201A (zh) 2005-01-05
KR100626785B1 (ko) 2006-09-21
DE60238131D1 (de) 2010-12-09
EP2193788B1 (en) 2015-10-21
GB0123400D0 (en) 2001-11-21
WO2003028705A1 (en) 2003-04-10
HUP0402394A2 (hu) 2005-09-28
ES2354687T3 (es) 2011-03-17
HK1067036A1 (en) 2005-04-01
CN1951390B (zh) 2010-11-03
RU2004113205A (ru) 2005-04-20
ZA200401300B (en) 2004-10-27
SI1432408T1 (sl) 2011-02-28
US20100221331A1 (en) 2010-09-02
CY1111119T1 (el) 2015-06-11
JP2005507897A (ja) 2005-03-24
AR097341A2 (es) 2016-03-09
NZ531599A (en) 2005-12-23
CN1951390A (zh) 2007-04-25
PE20030602A1 (es) 2003-08-27
BR0212922A (pt) 2004-10-13
AR036643A1 (es) 2004-09-22
ES2560106T3 (es) 2016-02-17
HK1141239A1 (en) 2010-11-05
CA2458455C (en) 2011-07-12
EP2193788A1 (en) 2010-06-09
KR20040037197A (ko) 2004-05-04
CO5390072A1 (es) 2004-04-30
JP2009102341A (ja) 2009-05-14
NZ542273A (en) 2007-11-30
JP5160386B2 (ja) 2013-03-13
PL367896A1 (en) 2005-03-07
NO20041270D0 (no) 2004-03-26
PT1432408E (pt) 2010-12-07
EP1432408B1 (en) 2010-10-27
PL209704B1 (pl) 2011-10-31
NO20041270L (no) 2004-06-14

Similar Documents

Publication Publication Date Title
HUP0402394A3 (en) Pharmaceutical compositions comprising colloidal silicon dioxide
GB0102342D0 (en) Pharmaceutical formulation
EP1407785A4 (en) MEDICAL COMPOSITIONS
GB0111597D0 (en) Pharmaceutical compositions
GB0319041D0 (en) Pharmaceutical Formulations
GB0118689D0 (en) Pharmaceutical formulation
PL366432A1 (en) Pharmaceutical formulation
GB0121715D0 (en) Pharmaceutical formulations
GB2380129B (en) Pharmaceutical formulations
GB0120701D0 (en) Pharmaceutical formulations
GB0103638D0 (en) Pharmaceutical formulations
IL161306A0 (en) Pharmaceutical formulation comprising (r)-bicalutamide
GB0105560D0 (en) Pharmaceutical formulations
GB0104752D0 (en) Pharmaceutical compositions
GB0125492D0 (en) Formulation
GB2382302B (en) Pharmaceutical compositions
GB0124455D0 (en) Pharmaceutical formulations
GB2375048B (en) Formulation
GB2396812B (en) Formulation
GB0104749D0 (en) Pharmaceutical formulation
GB0116619D0 (en) Formulation
GB0126732D0 (en) Pharmaceutical compositions
GB0112497D0 (en) Formulation
GB0121826D0 (en) Pharmaceutical compositions
HU0105050D0 (en) Pharmaceutical compositions